<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082339</url>
  </required_header>
  <id_info>
    <org_study_id>QTc25416</org_study_id>
    <nct_id>NCT03082339</nct_id>
  </id_info>
  <brief_title>Cortisone and QTc-Interval</brief_title>
  <official_title>Influence of Cortisone on QTc-interval</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asklepios Neurological Clinic Bad Salzhausen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asklepios Neurological Clinic Bad Salzhausen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Scientific and clinical data report about shortening of QTc-interval in patients treated with
      cortisone. Peal et al. analyzed chemical suppression of long QT syndrome (Type 2) in an in
      vivo zebrafish model. Their study revealed that flurandrenolide reproducibly suppressed the
      long QT phenotype via the glucocorticoid signaling pathway. In contrast to treatment with
      dexamethasone and testosterone, treatment with pure mineralocorticoid deoxycorticosterone
      acetate did not suppress long QT phenotype. Knockdown of the glucocorticoid receptor or,
      conversely, of the androgen receptor showed that flurandrenolide acting through the
      glucocorticoid receptor shortens ventricular action potentials. The mechanism is distinct
      from trafficking rescue of the defective zebrafish-ERG channel. The authors discuss that a
      drug normalizing repolarization would be a novel therapeutic tool in long QT syndrome and
      conclude that glucocorticoids could be expected to aid in the acute management of patients
      with long QT syndrome, e.g. in episodes of arrhythmic storm. In addition, corticoid induced
      normalization of the QT interval is reported in a patient with drug-induced prolongation of
      the QTc interval. Brostoff et al. report on a patient suffering from mucocutaneous
      leishmaniasis treated with sodium stibogluconate. During therapy, the QTc interval prolonged
      and returned to normal within 4 days after starting glucocorticoid therapy with prednisolone
      20 mg twice daily.

      Interrogation of the study:

        -  shortens cortisone the QTc-interval?

        -  how long is the interval until shortening of QTc-interval?

        -  is the effect prolonged?

        -  is the effect dose dependend?
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">April 25, 2020</completion_date>
  <primary_completion_date type="Actual">April 25, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Weeks</target_duration>
  <primary_outcome>
    <measure>Duration of QTc-interval</measure>
    <time_frame>1 week</time_frame>
    <description>daily ECG controls and measuring QTc-interval</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">105</enrollment>
  <condition>QTc-interval</condition>
  <arm_group>
    <arm_group_label>Neurology</arm_group_label>
    <description>Patients with inflammatory disease, especially multiple sclerosis, who underwent therapy with cortisone (&gt;=40mg/d)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pulmonology</arm_group_label>
    <description>Patients after LTX (under medication possible prologing QTc-interval), who underwent therapy with cortisone (&gt;=40mg/d)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cortisone</intervention_name>
    <description>Observation of QTc-interval</description>
    <arm_group_label>Neurology</arm_group_label>
    <arm_group_label>Pulmonology</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with inflammatory neurological (especially multiple sclerosis) and pulmological
        (after LTX) diseases, who underwent therapy with cortisone (&gt;= 40 mg/d).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who underwent therapy with cortisone (&gt;=40mg/d)

        Exclusion Criteria:

          -  patients with elevated intracranial pressure

          -  myocardial infarction within the last 6 months

          -  untreated stenosis of the coronary arteries

          -  right bundle branch block

          -  autoimmune disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Giessen</name>
      <address>
        <city>Gie√üen</city>
        <zip>35394</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Klinik Bad Salzhausen</name>
      <address>
        <city>Nidda</city>
        <zip>63667</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Brostoff JM, Lockwood DN. Glucocorticoids as a novel approach to the treatment of disabling side effects of sodium stibogluconate. J Clin Pharm Ther. 2012 Feb;37(1):122-3. doi: 10.1111/j.1365-2710.2011.01259.x. Epub 2011 Apr 4.</citation>
    <PMID>21457289</PMID>
  </reference>
  <reference>
    <citation>Peal DS, Mills RW, Lynch SN, Mosley JM, Lim E, Ellinor PT, January CT, Peterson RT, Milan DJ. Novel chemical suppressors of long QT syndrome identified by an in vivo functional screen. Circulation. 2011 Jan 4;123(1):23-30. doi: 10.1161/CIRCULATIONAHA.110.003731. Epub 2010 Nov 15.</citation>
    <PMID>21098441</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 12, 2017</study_first_submitted>
  <study_first_submitted_qc>March 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

